Akero Therapeutics, Inc. (AKRO)

Akero Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	234.21	249.77	150.48	187.24	64.79
Short-Term Investments	315.8	101.68	37.78	81.15	71.61
Cash & Cash Equivalents	550.01	351.45	188.26	268.39	136.4
Cash Growth	56.50%	86.68%	-29.86%	96.76%	79.53%
Other Current Assets	9.95	3.72	5.32	2.96	1.65
Total Current Assets	559.96	355.17	193.58	271.35	138.05
Property, Plant & Equipment	1.03	1.29	1.55	1.79	0
Long-Term Investments	19.28	0	0	0	0
Other Long-Term Assets	0	0.11	0.42	0.2	0.07
Total Long-Term Assets	20.31	1.4	1.97	1.99	0.07
Total Assets	580.27	356.57	195.55	273.34	138.12
Accounts Payable	7.04	7.97	6.71	3.43	0.95
Other Current Liabilities	12.09	11.12	18.42	9.68	8.42
Total Current Liabilities	19.13	19.08	25.13	13.11	9.37
Long-Term Debt	25.78	10.62	1.31	1.52	0
Other Long-Term Liabilities	0.05	0.31	0	0	0.02
Total Long-Term Liabilities	25.84	10.93	1.31	1.52	0.02
Total Liabilities	44.97	30.01	26.44	14.63	9.39
Total Debt	25.78	10.62	1.31	1.52	0
Debt Growth	142.78%	710.07%	-13.52%	-	-
Retained Earnings	-574.1	-422.34	-310.3	-209.53	-130.32
Comprehensive Income	0.27	0.04	-0.03	-0	-0.01
Shareholders' Equity	535.31	326.56	169.11	258.71	128.73
Net Cash / Debt	524.23	340.83	186.95	266.87	136.4
Net Cash / Debt Growth	53.81%	82.31%	-29.95%	95.65%	79.53%
Net Cash Per Share	9.97	8.74	5.37	8.48	9.05
Working Capital	540.83	336.09	168.45	258.23	128.68
Book Value Per Share	10.18	8.38	4.86	8.22	8.54

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).